Trials / Completed
CompletedNCT00320827
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
Phase 1 Study of CS-1008, a Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), Administered Weekly to Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose escalation study of CS-1008 (humanized anti-DR5 antibody) to determine the recommended Phase 2 dose and the maximum tolerated dose. Drug will be administered for six weeks and possibly up to 12 weeks depending on response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-1008 (humanized anti-DR5 antibody) |
Timeline
- First posted
- 2006-05-03
- Last updated
- 2007-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00320827. Inclusion in this directory is not an endorsement.